Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
about
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapyMolecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsThe Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic AnalysisGenomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Sound preconditioning therapy inhibits ototoxic hearing loss in mice.Advances in the management of squamous cell carcinoma of the head and neck.p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.Unraveling the molecular genetics of head and neck cancer through genome-wide approachesEpidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in ratsSTAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC CellsBalancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinomaFGFR2 signaling underlies p63 oncogenic function in squamous cell carcinomaERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.MERTK as a novel therapeutic target in head and neck cancer.XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.Emerging tyrosine kinase inhibitors for head and neck cancer.Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments.Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.Afatinib in the treatment of head and neck squamous cell carcinoma.Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.Defining the genomic landscape of head and neck cancers through next-generation sequencing.Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.Targeting EGFR and sonic hedgehog pathways for locally advanced eyelid and periocular carcinomasMolecular targeting in combination with platinum-based chemoradiotherapy in head and neck cancer treatment.Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib.Current Role of Dacomitinib in Head and Neck Cancer.Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.Erlotinib and gefitinib responsiveness in head and neck cancer cell lines--a comparing analysis with cetuximab.Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests.Lack of evidence for prognostic value of epidermal growth factor receptor intron-1 CA repeats for oral carcinomas.[Is (chemo)radiotherapy really the future standard in the treatment of oropharyngeal carcinoma?].Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
P2860
Q24187274-A3275805-0B5E-4C2E-ACB5-E5097D99496EQ26750719-78E0FD75-9F8D-4E39-BD83-F08ED6F139D5Q26797117-EAC04200-CD08-49BC-8A42-60F4A68A09ECQ27853189-ED67CDA9-947D-4FF0-A235-7678349544B8Q30248499-5172C945-A21C-4E0E-81F8-3E5D085B2FD7Q30447926-D66AFD54-5E5F-48EB-90F0-A6A31108E8A0Q33720431-16B8949A-72B9-443B-A41B-7F8EC0BEFFE4Q34683406-6A57CFCF-8F12-4DCD-AB55-7DD865E0701EQ35025009-78E9867F-5061-406F-A15E-086E6F93D383Q35413351-94116DD5-A242-45AF-BC29-E49F5F038C91Q36030906-F9951099-2198-41A9-9888-B3EB944E681AQ36371601-507E0EAA-4868-4988-AEEB-2EAA45280AC3Q36378279-695E9405-7D36-4B67-99FD-8BAD4826D301Q36656097-D73DEDE2-5466-4BDA-BD5A-FF373439276BQ36834852-0F94B452-661C-48B2-A278-260C9EC877A7Q37052955-D90375A9-9386-4346-8AC5-5F08C399417FQ37235591-7486DD98-833F-47CE-8536-995F0855B71DQ37362739-877275AD-3648-4164-B87D-BE5F687D71C0Q37725406-D4F3C4C0-6BB4-4510-BCE9-0E4C1B192A4AQ38149327-C7CDB1E6-5473-4B9C-B6AF-5145D286D600Q38155932-56B0888F-C6EC-4C57-B388-BC8F6B73CB3CQ38162129-8B067CDE-9653-4E61-982C-EDC6F80BC308Q38165227-0294AE45-0BAA-474E-801A-C54420672368Q38195721-F03955D6-C332-4790-9139-72C3270273A5Q38203938-FA969008-5D58-47A6-92F7-37FA5649F117Q38221292-39631F68-1F62-4F45-A1BE-4EC28879C080Q38240998-819A2BAD-BAAF-4385-946B-DDC786B741C7Q38251864-F4F0E413-5D31-4F66-989B-9A3776B79D21Q38382066-4E94CD36-3E2C-42E2-8E9E-265A71BEBEB1Q38756969-B2D328EB-566C-42F3-9198-0497C1666358Q38806115-169A7732-35E2-4DE5-AA95-FDC9BA9C2035Q38815481-A45A8E29-9198-4F7D-8326-ECFD264FFA7AQ38841850-F7905139-6E68-4FF7-B667-CE8A154AB95AQ38851114-10687F03-AD53-46D4-ADDF-082ABEFF8286Q38854643-40DE8AF1-BB82-4385-9850-6F519FB77D5BQ38892486-AB84C8B5-B461-4B4A-95EE-80DE16861799Q39696362-9A8ABB71-8F42-47C3-9473-3BD6A33E376BQ40354546-3F516DC2-8934-4028-A2DF-D41C5B6EC8EAQ40845161-60066DE1-22C0-4221-846D-E1A914DED6CEQ41133695-F2C3F30F-10A4-4E96-A7C6-E03468400B7D
P2860
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cisplatin and radiotherapy wit ...... : a randomized phase II trial.
@en
type
label
Cisplatin and radiotherapy wit ...... : a randomized phase II trial.
@en
prefLabel
Cisplatin and radiotherapy wit ...... : a randomized phase II trial.
@en
P2093
P50
P356
P1476
Cisplatin and radiotherapy wit ...... : a randomized phase II trial.
@en
P2093
Anand K Sharma
David X Wang
Eduardo Mendez
Furhan Yunus
Jay J Liao
Julie E Bauman
Keith D Eaton
Luis E Raez
Melissa Austin
Michael A Papagikos
P304
P356
10.1200/JCO.2012.46.3299
P407
P577
2013-03-04T00:00:00Z